Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (372)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (301)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 76 to 100 of 383
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Dapagliflozin for treating chronic kidney disease [ID6411]
Technology appraisal guidance
12 February 2025
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Technology appraisal guidance
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Technology appraisal guidance
TBC
DCVax-L for treating glioblastoma [ID836]
Technology appraisal guidance
TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]
Technology appraisal guidance
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897
Technology appraisal guidance
TBC
Diabetic retinopathy
NICE guideline
TBC
Diabetic retinopathy - ruboxistaurin [ID382]
Technology appraisal guidance
TBC
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment
Health technology evaluation
15 August 2024
Digitally enabled therapy for chronic tic disorders and Tourette Syndrome
Medical technologies guidance
19 December 2024
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants
Interventional procedures guidance
13 November 2024
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Technology appraisal guidance
11 September 2024
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Technology appraisal guidance
TBC
Drug eluting stents for treating coronary heart disease: late stage assessment
Health technology evaluation
TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
Technology appraisal guidance
TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235
Technology appraisal guidance
TBC
Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]
Technology appraisal guidance
TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
NICE guideline
TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Technology appraisal guidance
TBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Technology appraisal guidance
TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317
Technology appraisal guidance
TBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]
Technology appraisal guidance
TBC
Previous page
1
2
3
Current page
4
5
6
…
16
Page
4
of
16
Next page
Results per page
10
25
50
All
Back to top